Contact Us


Creating the Future of Healthcare with Partners~ SHIMADZU Advanced Healthcare ~ -Pioneering Partnerships for Advanced Healthcare-

Creating the Future of Healthcare with Partners~ SHIMADZU Advanced Healthcare ~ -Pioneering Partnerships for Advanced Healthcare-

Collaborative Research & Development for Advanced Healthcare utilizing the synergistic combination of Shimadzu's core technologies in analytical science and medical diagnostic imaging


What is Advanced Healthcare?

What is Advanced Healthcare?

Our technology is used in the research and development of ultra-early diagnostics, diagnostics, medical treatment, and prognosis phases to overcome diseases, such as cancer and lifestyle-related illnesses, and achieve healthier, longer life expectancies.

As society enters an era of aging demographics, there is a growing concern about how to maintain health at these advanced ages. Maintaining a healthy lifestyle as long as possible involves prevention, ultra-early diagnosis, medical treatment that minimizes the burden on the body and mind, and managing prognosis appropriately.

How can Shimadzu Corporation help?

As a pioneer in diagnostic X-ray imaging and a leader in mass spectrometry, Shimadzu has been working daily with researchers to develop solutions that will significantly change the future of healthcare, based on visualization using our medical and imaging technology and quantitative analysis using mass spectrometers.

Moving forward, we will continue to collaborate with pioneering researchers in efforts to develop solutions that extend healthy life expectancies and positively impact the healthcare environment of the future.

Shimadzu's Response to Dementia

Collaborative Research & Development for Advanced Healthcare

KYOLABS: SHIMADZU Healthcare R&D Center
for Researching Advanced Solutions

KYOLABS Shimadzu's collaborative laboratories

Shimadzu is accelerating efforts to develop healthcare solutions based on its strengths in analytical & measuring technology and medical diagnostic imaging technology. We aim to contribute to sustainable growth in aging societies and to support the development of foods that help improve human health. To achieve those objectives, Shimadzu opened the Healthcare R&D Center in June 2019. The center includes the KYOLABS collaborative laboratories for research and development.

Read More

Related Topics

November 22, 2022
To Develop Japan’s First Blood Biomarker-Based Diagnostic Workflow for Dementia
Shimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research
July 25, 2022
Proof of Concept of Diagnostic Aid Technology for Depression Using Blood Tests
Together with Kyushu University and HMT, Bringing the Testing Model to Society
November 4, 2021
Antibody monitoring technology using mass spectrometry contributed to a determination of clinical outcomes for the treatment of rheumatoid arthritis by Kyoto University Hospital and Shimadzu Corporation
November 1, 2021
In Collaboration with the NCVC, Establishment of the World’s First Technique for Detecting a Genetic Risk Factor for Cerebrovascular Disease Unique to East Asia
Shimadzu Techno-Research Commences a Contract Analysis Service for Medical Institutions for Research Purposes Only
October 11, 2021
Mass spectrometry technology contributed to a biomarker discovery for antibody therapeutics in cancer immunotherapy
Discovering a Biomarker for the Clinical Outcome of Cancer Patients treated with ipilimumab by Providence Cancer Institute, USA and Shimadzu Corporation
July 21, 2021
Shimadzu Releases Amyloid MS CL System for Measuring Candidate Substance Potentially Causing Alzheimer’s Disease
System Requires Testing Only a Small Quantity of Blood, which Reduces Burden to Patients
June 2, 2021
Notice Regarding the Signing of Basic Agreement of Business Partnership between SHIMADZU and SHIONOGI for Wastewater Surveillance for Viruses in the Field of Infectious Diseases, Including Novel Coronavirus
May 26, 2021
Mass spectrometry technology contributed to the advancement of cancer immunotherapy Discovering a Biomarker for Predicting the Clinical Outcome of Cancer Patients treated with a New Combination Immunotherapy in a Phase I Clinical Trial Conducted by Providence Cancer Institute, USA
May 6, 2021
Shimadzu Scientific Instruments to Collaborate on Anti-aging Research at Washington University School of Medicine
March 1, 2021
Release of World’s First TOF-PET System Specialized for Head and Breast Examinations
Scanning Brain Tumors, Epilepsy and Breast Cancers with Outstanding Accuracy and Even Supporting Alzheimer’s and Other Dementia Researches
January 28, 2021
Changi General Hospital and Shimadzu (Asia Pacific) jointly launch centre to conduct mass spectrometry-based clinical testing and research for personalised treatment
January 21, 2021
Sales of Novel Coronavirus PCR Testing Reagent Kits outside Japan Exports Began
December 21, 2020
Release of Fully-Automatic PCR Testing System for Clinics
Contributes to Japan’s COVID-19 Testing Capabilities
November 19, 2020
Shimadzu Announces the Start of Its Blood-Based Amyloid Mass Spectrometry Service Dedicated to Drug Discovery and Development
November 13, 2020
Tohoku University and Shimadzu Jointly Announce a New Breath Test for Detecting COVID-19
September 17, 2020
Acquisition of the approval for marketing the Novel Coronavirus (SARS-CoV-2) Detection Reagent Kit as an In Vitro Diagnostic Product
June 5, 2020
Research on Alzheimer´s
Early detection of Alzheimer’s biomarkers
April 13, 2020
Release of the “2019 Novel Coronavirus Detection Kit”
Reduces labor and halves detection time
November 14, 2019
Global Pharma Summit 2019 Report
July 9, 2019
Shimadzu Global Innovation Summit 2019